A clinical trial to study the effects of three different formulations of brimonidine in patients of primary open angle glaucoma.
- Conditions
- Health Condition 1: null- primary open angle glaucoma
- Registration Number
- CTRI/2013/05/003666
- Lead Sponsor
- nil
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 60
1.Minimum age of 18 years
2.Unilateral/bilateral primary open angle glaucoma. Patients with bilateral primary open angle glaucoma were treated for both eyes but only one eye was considered as study eye.
3.IOP >21mm Hg.
1.History of acute angle closure glaucoma
2.History of any intraocular surgery within 6 months prior to study.
3.History of argon laser trabeculoplasty within 6 months prior to study.
4.All patients with established diagnosis of secondary glaucoma.
5.Pregnant / lactating females.
6.Women of child bearing potential who are not using contraceptive protection.
7.Any known sensitivity to the study drugs.
8.Ocular inflammation or infection.
9.Inability to cope up with the treatment plan.
10. Have participated in any other clinical study within 3 months prior to study.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Mean Intraocular pressure reduction from baseline to 6 weeks.Timepoint: 2 weeks <br/ ><br>4 weeks <br/ ><br>6 weeks
- Secondary Outcome Measures
Name Time Method side effects of three formulations of brimonidineTimepoint: 2 weeks <br/ ><br>4 weeks 6 weeks